Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ALKS 4230 |
Trade Name | |
Synonyms | RDB 1450|Nemvaleukin alfa|ALKS-4230|ALKS4230|RBD1450|RBD-1450 |
Drug Descriptions |
ALKS 4230 is a fusion protein of IL2 and IL2RA, which activates effector lymphocytes upon binding to intermediate affinity IL2 receptors to enhance cell death of tumor cells (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4088, PMID: 32317293). |
DrugClasses | |
CAS Registry Number | 2315268-27-8 |
NCIT ID | C128107 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ALKS 4230 | ALKS 4230 | 0 | 5 |
ALKS 4230 + Pembrolizumab | ALKS 4230 Pembrolizumab | 0 | 4 |